Timeline

We began development of Melaseq, the worlds first non-invasive cancer biomarker in 2016, building on our combined decades of research in the field of cancer genomics and assay development.

Click to view an annotated timeline of our Melaseq development progress and company milestones.

2016
November 28

Geneseq Biosciences founded

Geneseq Biosciences founded
Company launched in Melbourne, Australia to translate the latest developments in cancer…
December 1

Melanoma Genomic database created

Melanoma Genomic database created
Blood samples from melanoma patients procured from international clinical research biobanks Cureline…
2017
March 28

Melaseq algorithm developed

Melaseq algorithm developed
Geneseq melanoma database mined to identify the optimal set of diagnostic circulating…
September 22

Accepted to Melbourne Health Accelerator Spring 2017 Cohort

Accepted to Melbourne Health Accelerator Spring 2017 Cohort
Geneseq Biosciences invited to participate in Australia’s first hospital ‘in-situ’ accelerator program,…
October 3

Melaseq patent application submitted

Melaseq patent application submitted
Patent “A method of diagnosis and staging of melanoma using microRNA gene…
October 11

Patient recruitment commenced for validation study 2

Patient recruitment commenced for validation study 2
Melaseq analysis of patient blood samples (i) before and (ii) 2-4 weeks…
October 18

World Melanoma Congress 2017 Presentation

World Melanoma Congress 2017 Presentation
Melaseq development and validation results presented at the premier joint congress on…
December 15

Graduation from Melbourne Health Accelerator (MHx)

Graduation from Melbourne Health Accelerator (MHx)
Completed the Melbourne Health Incubator program and pitched to several hundred colleagues,…
2018
March 12

Melaseq published in the British Journal of Cancer

Melaseq published in the British Journal of Cancer
Melaseq is one step closer to being available for use in Australia…
August 9

Second Melaseq clinical study to be published in Melanoma Research

Second Melaseq clinical study to be published in Melanoma Research
The world’s first blood test for Melanoma, developed by Geneseq Biosciences (Melbourne,…
October 5

Partnership with Australian Clinical Labs

Partnership with Australian Clinical Labs
Geneseq Biosciences and Australian Clinical Labs today announced they will partner to…
2019
January 3

Melaseq Analytical Validation Studies Commenced

Melaseq Analytical Validation Studies Commenced
Laboratory work commenced at Australian Clinical Labs Clayton (VIC) headquarters, generating Melaseq accuracy…
February 5

Third Melaseq validation study published in PLOS ONE

Third Melaseq validation study published in PLOS ONE
New research published in PLOS ONE, shows that the Melaseq™ test can…
August 15

Melaseq Prospective Validation Study Approved

Melaseq Prospective Validation Study Approved
Permission to commence an extended technical and clinical validation of Melaseq, using…
2020
February 1

Patient Recruitment Commenced for Melaseq Clinical Validation Study

Patient Recruitment Commenced for Melaseq Clinical Validation Study
Patient recruitment and specimen collection commenced at multiple leading skin cancer clinics…
2021
June 29

Melaseq-FFPE Validation Study Completed & Published

Melaseq-FFPE Validation Study Completed & Published
Multiple international studies have described the challenge of providing accurate and reproducible…